



INFORMATION: Access to TOUJEO[®] (insulin glargine 300 units/mL)

Sanofi, the manufacturer of Toujeo[®] (insulin glargine 300 units/mL), wish to update you regarding access in Australia.

Toujeo[®] was added to the Australian Register of Therapeutic Goods (ARTG) on 30 June 2015 and received a positive recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC) on 31 July 2015. Since then, the company has been in ongoing negotiations with the Government to secure a listing on the Pharmaceutical Benefits Scheme (PBS).

Despite a first time recommendation from the PBAC to list Toujeo[®], the Department of Health and Sanofi are unable to reach an agreement satisfactory to both parties to finalise the listing.

Sanofi is disappointed Toujeo[®] will not be available on the PBS to patients with diabetes in the foreseeable future, but remains committed to access and continues to explore options.

Sanofi conducted a Product Familiarisation Program (PFP) to give prescribers the opportunity to evaluate and become familiar with the product. It was planned for the PFP to cease on 1 May 2016. However, as Sanofi continues to explore options for wider access we have decided to extend access to patients previously enrolled in the PFP until further notice.

If you have any questions, or would like further detail about the matters outlined in this letter, please contact Sanofi on 1800 818 906 or medinfo.australia@sanofi.com.

Yours sincerely,

A handwritten signature in black ink, appearing to read "David Russell", written in a cursive style.

David Russell
Business Unit Head
Diabetes and Cardiovascular Care

SAANZ.TJO.16.05.0086a
Date prepared May 2016